Disease Info Card

Mixed Connective Tissue Disease

Information about Mixed Connective Tissue Disease: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Mixed Connective Tissue Disease

Most recent studies have shown that Mixed Connective Tissue Disease shares some biological mechanisms with arthritis, autoimmune-diseases, autoimmune-reaction, collagen-diseases, connective-tissue-diseases, dermatomyositis, diffuse-scleroderma, hypertensive-disease, lung-diseases, lupus-erythematosus-systemic, myositis, polymyositis, pulmonary-hypertension, raynaud-disease, rheumatism, rheumatoid-arthritis, scleroderma, sclerosis, sjogrens-syndrome, vasculitis.

Among the many pathways, these few ones have gauged particular interests from scientists studying Mixed Connective Tissue Disease, and have been seen in publications frequently: Cell Activation, Cell Death, Cell Proliferation, Coagulation, Endothelial Cell Activation, Excretion, Glycosylation, Hypersensitivity, Immune Complex Formation, Immune Response, Localization, Macrophage Activation, Metaphase, Pathogenesis, Peristalsis, Phagocytosis, Reflex, Secretion, Translation, Vasoconstriction

Quite a number of genes have been found to play important roles in Mixed Connective Tissue Disease, such as C3, CALR, CDSN, CRP, DMPK, ENAH, HLA-DRB4, HNRNPC, IL2, IL6, PAH, PRB1, PRTN3, RNPC3, SNRNP70, SS18L1, SSB, TNF, TRIM21. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.